EXAS
Exact Sciences CorpstockNASDAQ
InactiveMar 20, 2026
104.91USD+0.953%(+0.99)21,561,523
Loading…
Loading…
Sector
Healthcare
Industry
Medical Diagnostics & Research
CEO
Kevin Conroy
HQ
Madison, Wisconsin, USA
Oct 24, 2026
Oct 21, 2026
50 new pitches found in hedge fund reports this week ·
Stock Analysis Compilation
Oct 7, 2026
50 new pitches found in hedge fund reports this week ·
Stock Analysis Compilation
Oct 1, 2026
Sep 30, 2026
Abbott launches Freenome’s colorectal cancer screening test ·
MedTech Dive
EXAS Profile
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
EXAS Performance
| Period | Price | Date | Change |
|---|
